Skip to search formSkip to main contentSkip to account menu

amenamevir

A novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2. Amenamenir stabilizes the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
In July 2017, Japan’s Ministry of Health, Labor and Welfare issued a marketing authorization valid throughout Japan for N‐(2,6… 
2017
2017
Amenamevir is a potent helicase–primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as… 
2017
2017
IntroductionAmenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound available for the treatment of varicella–zoster… 
Review
2017
Review
2017
Valacyclovir and famciclovir enabled successful systemic therapy for treating herpes simplex virus (HSV) and varicella zoster… 
Review
2016
Review
2016
Review
2015
Review
2015
Purpose of review The mainstay of antiviral therapy for the alpha-herpesviruses [herpes simplex virus (HSV)-1, HSV-2, and… 
Review
2015
Review
2015
The seminal discovery of acyclovir 40 years ago heralded the modern era of truly selective antiviral therapies and this drug… 
Highly Cited
2010
Highly Cited
2010
OBJECTIVES To evaluate and describe the anti-herpesvirus effect of ASP2151, amenamevir, a novel non-nucleoside oxadiazolylphenyl… 
2010
2010
Methods: The inhibitory effect of ASP2151 on enzymatic activities associated with a recombinant HSV-1 helicase–primase complex…